Compare MRCC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCC | QNCX |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.2M | 139.2M |
| IPO Year | 2012 | 2019 |
| Metric | MRCC | QNCX |
|---|---|---|
| Price | $6.63 | $4.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $8.00 | $7.75 |
| AVG Volume (30 Days) | 100.5K | ★ 946.4K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 15.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $0.72 |
| 52 Week High | $8.85 | $3.73 |
| Indicator | MRCC | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 81.13 |
| Support Level | $6.36 | $2.92 |
| Resistance Level | $6.55 | $3.73 |
| Average True Range (ATR) | 0.19 | 0.39 |
| MACD | 0.07 | 0.16 |
| Stochastic Oscillator | 98.81 | 89.69 |
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.